Market LIVE
Published markets; coverage varies by country
Product profile · United States

TEMBEXA

 ·  Patent Litigation & Settlement History ↓

IngredientBRINCIDOFOVIR
Application typeNDA
Application214460
Product001
Dosage formSUSPENSION
RouteORAL
Strength10MG/ML
Approval date2021-06-04
Marketing statusPrescription
Status event—
ApplicantEMERGENT BIODEFENSE
Product source

Current GenericRadar decision

Year2028
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeREGULATORY_EXCLUSIVITY
Anchor date2028-06-04
Patent anchor—
Exclusivity anchor2028-06-04
Protection date2034-07-30
First Final ANDA—
Status event—

Whole-scope ODE-354 anchor2028-06-04; FormB DP patent9303051 tail2034-07-30; DEEP_REVIEW; exact Final ANDA not identified, not a generic-absence determination

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
93030512034-07-30DS/DP/U U-3165NNDP
| B1C01 issued-claim review2026-10-14: DP
———
93030512034-07-30ORANGE_BOOK U-3165NNDP
English description not available.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
ODE-354—2028-06-04————Source
ODE-3542021-06-042028-06-04English description not available.YY2028-06-04Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (3)
TypeDateRoleBasisSource
PATENT2034-07-30FTO_TAILEnglish description not available.Source
REGULATORY_EXCLUSIVITY—CANONICAL_ANCHOREnglish description not available.Source
REGULATORY_STATUS2028-06-04CANONICAL_DECISIONWhole-scope ODE-354 anchor2028-06-04; FormB DP patent9303051 tail2034-07-30; DEEP_REVIEW; exact Final ANDA not identified, not a generic-absence determinationSource
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.